BioCentury | Mar 24, 2008
Finance

Nomura's investments

...$52M series C, 2004 3i Group; Close Finsbury Eurotech; MB Venture Capital Fund; Merlin Biosciences; Finsbury Life Sciences...
BioCentury | Feb 26, 2007
Finance

Ebb & Flow

A profitable, private biotech company seems almost an oxymoron, but that’s what Ikaria and its investors are creating with last week’s acquisition of INO Therapeutics for $500 million to be paid in cash to INO’s...
BioCentury | Dec 19, 2005
Strategy

Cyclacel funding history

...Development Capital; Vertex Management; GeneChem Technologies Venture Fund; Singapore Economic Development Board; Noble Grossart; Quester; Finsbury Life Sciences...
...DC Thomson; NIF Ventures; Quest for Growth; UOB Venture Management; BankInvest; Biomedical Sciences Investment Fund; Finsbury Life Sciences...
BioCentury | May 23, 2005
Finance

U.S. investment in Europe

...Novo A/S Arakis U.K. $52.0 Novo A/S; Scottish Equity Partnership; Scottish Widows Investment Partnership; 3i; Finsbury Life Sciences...
BioCentury | Sep 13, 2004
Finance

Ebb & Flow

...by Novo and Scottish Equity Partners. Other investors included Scottish Widows Investment Partnership; 3i; the Finsbury Life Sciences...
BioCentury | May 17, 2004
Finance

U.S. investment in Europe

...Quest for Growth; UOB Venture Management; PTE Ltd.; BankInvest; Biomedical Sciences Investment Fund Pte Ltd.; Finsbury Life Sciences...
BioCentury | Jun 14, 2001
Financial News

Cyclacel raises 34 million

...Development Capital; Vertex Management; GeneChem Management; Singapore Economic Development Board; Noble Grossart; Quester Capital Management; Finsbury Life Sciences...
BioCentury | Mar 13, 2000
Finance

Changing of the guard

...FTSE 100 or the second tier FTSE 250 index," noted Andrew Clark, portfolio manager at Finsbury Life Sciences...
BioCentury | Feb 28, 2000
Finance

Dickensian winter disappears

OXFORD - London biotech stocks, like their U.S. counterparts, have seen massive price increases since mid-October, with BioCentury's London Index rising 132 percent over the period. Various fund managers see little evidence that biotech enthusiasm will...
BioCentury | Jan 10, 2000
Finance

Spreading the wealth

...at E35.23 ($35.83) with a market cap of E403 million ($410 million). Andrew Clark of Finsbury Life Sciences...
Items per page:
1 - 10 of 10
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...$52M series C, 2004 3i Group; Close Finsbury Eurotech; MB Venture Capital Fund; Merlin Biosciences; Finsbury Life Sciences...
BioCentury | Feb 26, 2007
Finance

Ebb & Flow

A profitable, private biotech company seems almost an oxymoron, but that’s what Ikaria and its investors are creating with last week’s acquisition of INO Therapeutics for $500 million to be paid in cash to INO’s...
BioCentury | Dec 19, 2005
Strategy

Cyclacel funding history

...Development Capital; Vertex Management; GeneChem Technologies Venture Fund; Singapore Economic Development Board; Noble Grossart; Quester; Finsbury Life Sciences...
...DC Thomson; NIF Ventures; Quest for Growth; UOB Venture Management; BankInvest; Biomedical Sciences Investment Fund; Finsbury Life Sciences...
BioCentury | May 23, 2005
Finance

U.S. investment in Europe

...Novo A/S Arakis U.K. $52.0 Novo A/S; Scottish Equity Partnership; Scottish Widows Investment Partnership; 3i; Finsbury Life Sciences...
BioCentury | Sep 13, 2004
Finance

Ebb & Flow

...by Novo and Scottish Equity Partners. Other investors included Scottish Widows Investment Partnership; 3i; the Finsbury Life Sciences...
BioCentury | May 17, 2004
Finance

U.S. investment in Europe

...Quest for Growth; UOB Venture Management; PTE Ltd.; BankInvest; Biomedical Sciences Investment Fund Pte Ltd.; Finsbury Life Sciences...
BioCentury | Jun 14, 2001
Financial News

Cyclacel raises 34 million

...Development Capital; Vertex Management; GeneChem Management; Singapore Economic Development Board; Noble Grossart; Quester Capital Management; Finsbury Life Sciences...
BioCentury | Mar 13, 2000
Finance

Changing of the guard

...FTSE 100 or the second tier FTSE 250 index," noted Andrew Clark, portfolio manager at Finsbury Life Sciences...
BioCentury | Feb 28, 2000
Finance

Dickensian winter disappears

OXFORD - London biotech stocks, like their U.S. counterparts, have seen massive price increases since mid-October, with BioCentury's London Index rising 132 percent over the period. Various fund managers see little evidence that biotech enthusiasm will...
BioCentury | Jan 10, 2000
Finance

Spreading the wealth

...at E35.23 ($35.83) with a market cap of E403 million ($410 million). Andrew Clark of Finsbury Life Sciences...
Items per page:
1 - 10 of 10